

March 5, 2008

Astellas Reaches Settlement Agreement with Taiyo on the Oral Cephalosporin Antibiotic Cefzon[®] Litigations

Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has reached a settlement agreement with Taiyo Yakuhin Co., Ltd. (“Taiyo”; headquarters: Nagoya), which contains provisions of settlement payment by Taiyo, to end a series of disputes on its oral cephalosporin antibiotic cefdinir (brand name: Cefzon[®]). Taiyo obtained NHI prices for its generic products of cefdinir and manufactured / marketed them while Astellas’ patent on cefdinir has been valid. In response to those actions, Astellas has filed lawsuits claiming damages and proceeding for injunction to restrain Taiyo from manufacturing and marketing such generic products.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com